General Announcement::New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody
Issuer & Securities
Issuer/ ManagerGLENMARK PHARMACEUTICALS LIMITED
SecuritiesGLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled SecurityNo
Announcement Details
Announcement Title General Announcement
Date & Time of Broadcast19-Feb-2018 12:38:28
StatusNew
Announcement Sub TitleNew Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody
Announcement ReferenceSG180219OTHRRCCA
Submitted By (Co./ Ind. Name)Glenmark Pharmaceuticals Limited
DesignationCompany Secretary & Compliance Officer
Effective Date and Time of the event19/02/2018 10:00:00
Description (Please provide a detailed description of the event in the box below)Sub: Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.
Attachments
SGX_PR_19022018.pdf
Total size =852K